Amgenvs.Regeneron
AMGN vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 2.7× larger than Regeneron by market cap; Regeneron trades at the lower P/E (19.0 vs 25.8); year to date, Amgen leads (+35.6% vs +7.3%).
Side by side
| AMGN | REGN | |
|---|---|---|
| Market cap | $226B | $82.2B |
| Price | $442.24 | $833.56 |
| Today | −0.4% | +0.6% |
| Return YTD | +35.6% | +7.3% |
| Return 1Y | +51.1% | +40.5% |
| P/E | 25.8 | 19.0 |
| P/S | 5.9 | 5.3 |
| P/B | 19.3 | 2.6 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →RegeneronREGN
Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.
Full REGN profile →More AMGN & REGN comparisons
Other head-to-heads in the Biotech & innovation segment.